The ‘uberization of policing’? How police negotiate and operationalise predictive policing technology

Predictive policing generally refers to police work that utilises strategies, algorithmic technologies, and big data to generate near-future predictions about the people and places deemed likely to be involved in or experience crime. Claimed benefits of predictive policing centre on the technology’s ability to enable pre-emptive police work by automating police decisions. The goal is that officers will rely on computer software and smartphone applications to instruct them about where and who to police just as Uber drivers rely on similar technologies to instruct them about where to pick up passengers. Unfortunately, little is known about the experiences of the in-field users of predictive technologies. This article helps fill this gap by addressing the under researched area of how police officers engage with predictive technologies. As such, data is presented that outlines the findings of a qualitative study with UK police organisations involved in designing and trialing predictive policing software. Research findings show that many police officers have a detailed awareness of the limitations of predictive technologies, specifically those brought about by errors and biases in input data. This awareness has led many officers to develop a sceptical attitude towards predictive technologies and, in a few cases, these officers have expressed a reluctance to use predictive technologies. Based on these findings, this paper argues that claims about predictive software’s ability to neutralise the subjectivity of police work overlooks the ongoing struggles of the police officer to assert their agency and mediate the extent to which predictions will be trusted and utilised

Effective interaction between helical bio-molecules

The effective interaction between two parallel strands of helical bio-molecules, such as deoxyribose nucleic acids (DNA), is calculated using computer simulations of the "primitive" model of electrolytes. In particular we study a simple model for B-DNA incorporating explicitly its charge pattern as a double-helix structure. The effective force and the effective torque exerted onto the molecules depend on the central distance and on the relative orientation. The contributions of nonlinear screening by monovalent counterions to these forces and torques are analyzed and calculated for different salt concentrations. As a result, we find that the sign of the force depends sensitively on the relative orientation. For intermolecular distances smaller than $6\AA$ it can be both attractive and repulsive. Furthermore we report a nonmonotonic behaviour of the effective force for increasing salt concentration. Both features cannot be described within linear screening theories. For large distances, on the other hand, the results agree with linear screening theories provided the charge of the bio-molecules is suitably renormalized.Comment: 18 pages, 18 figures included in text, 100 bibliog

A clinical trial of progesterone for severe traumatic brain injury

Background Progesterone has been associated with robust positive effects in animal models of traumatic brain injury (TBI) and with clinical benefits in two phase 2 randomized, controlled trials. We investigated the efficacy and safety of progesterone in a large, prospective, phase 3 randomized clinical trial. Methods We conducted a multinational placebo-controlled trial, in which 1195 patients, 16 to 70 years of age, with severe TBI (Glasgow Coma Scale score, 648 [on a scale of 3 to 15, with lower scores indicating a reduced level of consciousness] and at least one reactive pupil) were randomly assigned to receive progesterone or placebo. Dosing began within 8 hours after injury and continued for 120 hours. The primary efficacy end point was the Glasgow Outcome Scale score at 6 months after the injury. Results Proportional-odds analysis with covariate adjustment showed no treatment effect of progesterone as compared with placebo (odds ratio, 0.96; confidence interval, 0.77 to 1.18). The proportion of patients with a favorable outcome on the Glasgow Outcome Scale (good recovery or moderate disability) was 50.4% with progesterone, as compared with 50.5% with placebo. Mortality was similar in the two groups. No relevant safety differences were noted between progesterone and placebo. Conclusions Primary and secondary efficacy analyses showed no clinical benefit of progesterone in patients with severe TBI. These data stand in contrast to the robust preclinical data and results of early single-center trials that provided the impetus to initiate phase 3 trials. (Funded by BHR Pharma; SYNAPSE ClinicalTrials.gov number, NCT01143064 .)